A Phase I Study to Evaluate the Pharmacokinetics, Safety and Antiviral Effects of Concurrent Administration of Zidovudine (AZT) and 2'3'-Dideoxyinosine (ddI) in Patients With Human Immunodeficiency Virus (HIV)
NCT ID: NCT00002014
Last Updated: 2005-06-24
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
INTERVENTIONAL
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
TREATMENT
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Zidovudine
Didanosine
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Allowed:
* Acyclovir not to exceed two 14-day courses of therapy during trial. Discontinue ddI while receiving acyclovir.
Patients must have the following:
* Positive HIV antibody using federally licensed ELISA test kit.
* CD4 counts \< 400 on two consecutive visits within one month prior to entry.
Prior Medication:
Allowed:
* Zidovudine (AZT) if treated for less than 120 days.
* Pharmacologic doses of steroids if given for management of Pneumocystis carinii pneumonia (PCP) (not to exceed 21 days).
Exclusion Criteria
Patients with the following conditions or symptoms are excluded:
\- Visceral or progressive Kaposi's sarcoma (KS) (defined by \> 10 new lesions in the thirty days prior to entry) or patients who require chemotherapy or radiation therapy for Kaposi's sarcoma. Other concurrent neoplasms other than basal cell carcinoma of skin or in situ carcinoma of the cervix. Malabsorption as defined by persistent diarrhea ( \> 4 stools/day for four weeks) which is unresponsive to antidiarrheal agents. Opportunistic infection requiring maintenance therapy. History of Central Nervous System opportunistic infections (e.g., toxoplasmosis, cryptococcosis). History of seizure disorders. Prior history of pancreatitis. History of peripheral neuropathy or any significant signs or symptoms of neurological disease. Examinations for peripheral neuropathy should assess changes in extremities. Clinically significant hyperuricemia (tophaceous gout, urate nephropathy). History of cardiomyopathy.
Concurrent Medication:
Excluded:
* Intravenous pentamidine.
* Intravenous trimethoprim / sulfamethoxazole.
* Alcohol.
* Suppressive acyclovir therapy (see Inclusion Medications).
* Allopurinol.
* Probenecid.
* Isoniazid (INH).
* Dipyridamole.
Concurrent Treatment:
Excluded:
* Radiation therapy for Kaposi's sarcoma.
Patients with the following are excluded:
* Zidovudine (AZT) intolerance as evidenced by inability to tolerate at least 600 mg AZT daily.
* Previously intolerant to didanosine (ddI) evidenced by peripheral neuropathy or seizures or pancreatitis or gastrointestinal toxicity or hematologic toxicity.
* Diseases or conditions listed under Patient Exclusion Co-existing Conditions.
Prior Medication:
Excluded:
* Zidovudine (AZT) for \> 120 days.
* Dideoxycytidine (ddC).
* Excluded within 30 days of study entry:
* Antiretroviral therapy.
* Immunomodulators.
* Biological response modifiers.
* Cytotoxic chemotherapy for Kaposi's sarcoma.
* Excluded within 60 days of study entry:
* Ribavirin.
Prior Treatment:
Excluded within 2 weeks of study entry:
* Transfusions.
* Excluded within 30 days of study entry:
* Radiation therapy for Kaposi's sarcoma.
Active substance abuse that would impair compliance with study procedures.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Glaxo Wellcome
INDUSTRY
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
San Francisco AIDS Clinic / San Francisco Gen Hosp
San Francisco, California, United States
Univ of Miami School of Medicine
Miami, Florida, United States
New England Med Ctr
Boston, Massachusetts, United States
Univ of Washington
Seattle, Washington, United States
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Lorenzen S, Quante M, Rauscher I, Slotta-Huspenina J, Weichert W, Feith M, Friess H, Combs SE, Weber WA, Haller B, Angele M, Albertsmeier M, Blankenstein C, Kasper S, Schmid RM, Bassermann F, Schwaiger M, Liffers ST, Siveke JT. PET-directed combined modality therapy for gastroesophageal junction cancer: Results of the multicentre prospective MEMORI trial of the German Cancer Consortium (DKTK). Eur J Cancer. 2022 Nov;175:99-106. doi: 10.1016/j.ejca.2022.07.027. Epub 2022 Sep 10.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
01
Identifier Type: -
Identifier Source: secondary_id
052A
Identifier Type: -
Identifier Source: org_study_id